281 related articles for article (PubMed ID: 26201449)
1. Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry.
Kay C; Collins JA; Skotte NH; Southwell AL; Warby SC; Caron NS; Doty CN; Nguyen B; Griguoli A; Ross CJ; Squitieri F; Hayden MR
Mol Ther; 2015 Nov; 23(11):1759-1771. PubMed ID: 26201449
[TBL] [Abstract][Full Text] [Related]
2. A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease.
Kay C; Collins JA; Caron NS; Agostinho LA; Findlay-Black H; Casal L; Sumathipala D; Dissanayake VHW; Cornejo-Olivas M; Baine F; Krause A; Greenberg JL; Paiva CLA; Squitieri F; Hayden MR
Am J Hum Genet; 2019 Dec; 105(6):1112-1125. PubMed ID: 31708117
[TBL] [Abstract][Full Text] [Related]
3. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.
Carroll JB; Warby SC; Southwell AL; Doty CN; Greenlee S; Skotte N; Hung G; Bennett CF; Freier SM; Hayden MR
Mol Ther; 2011 Dec; 19(12):2178-85. PubMed ID: 21971427
[TBL] [Abstract][Full Text] [Related]
4. Sequence-Level Analysis of the Major European Huntington Disease Haplotype.
Lee JM; Kim KH; Shin A; Chao MJ; Abu Elneel K; Gillis T; Mysore JS; Kaye JA; Zahed H; Kratter IH; Daub AC; Finkbeiner S; Li H; Roach JC; Goodman N; Hood L; Myers RH; MacDonald ME; Gusella JF
Am J Hum Genet; 2015 Sep; 97(3):435-44. PubMed ID: 26320893
[TBL] [Abstract][Full Text] [Related]
5. Personalized gene silencing therapeutics for Huntington disease.
Kay C; Skotte NH; Southwell AL; Hayden MR
Clin Genet; 2014 Jul; 86(1):29-36. PubMed ID: 24646433
[TBL] [Abstract][Full Text] [Related]
6. Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes.
Baine FK; Kay C; Ketelaar ME; Collins JA; Semaka A; Doty CN; Krause A; Greenberg LJ; Hayden MR
Eur J Hum Genet; 2013 Oct; 21(10):1120-7. PubMed ID: 23463025
[TBL] [Abstract][Full Text] [Related]
7. The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America.
Kay C; Tirado-Hurtado I; Cornejo-Olivas M; Collins JA; Wright G; Inca-Martinez M; Veliz-Otani D; Ketelaar ME; Slama RA; Ross CJ; Mazzetti P; Hayden MR
Eur J Hum Genet; 2017 Feb; 25(3):332-340. PubMed ID: 28000697
[TBL] [Abstract][Full Text] [Related]
8. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
[TBL] [Abstract][Full Text] [Related]
9. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients.
Skotte NH; Southwell AL; Østergaard ME; Carroll JB; Warby SC; Doty CN; Petoukhov E; Vaid K; Kordasiewicz H; Watt AT; Freier SM; Hung G; Seth PP; Bennett CF; Swayze EE; Hayden MR
PLoS One; 2014; 9(9):e107434. PubMed ID: 25207939
[TBL] [Abstract][Full Text] [Related]
10. Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9.
Shin JW; Kim KH; Chao MJ; Atwal RS; Gillis T; MacDonald ME; Gusella JF; Lee JM
Hum Mol Genet; 2016 Oct; 25(20):4566-4576. PubMed ID: 28172889
[TBL] [Abstract][Full Text] [Related]
11. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.
Sun X; Marque LO; Cordner Z; Pruitt JL; Bhat M; Li PP; Kannan G; Ladenheim EE; Moran TH; Margolis RL; Rudnicki DD
Hum Mol Genet; 2014 Dec; 23(23):6302-17. PubMed ID: 25035419
[TBL] [Abstract][Full Text] [Related]
12. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
[TBL] [Abstract][Full Text] [Related]
13. Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells.
Drouet V; Ruiz M; Zala D; Feyeux M; Auregan G; Cambon K; Troquier L; Carpentier J; Aubert S; Merienne N; Bourgois-Rocha F; Hassig R; Rey M; Dufour N; Saudou F; Perrier AL; Hantraye P; Déglon N
PLoS One; 2014; 9(6):e99341. PubMed ID: 24926995
[TBL] [Abstract][Full Text] [Related]
14. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia.
Warby SC; Visscher H; Collins JA; Doty CN; Carter C; Butland SL; Hayden AR; Kanazawa I; Ross CJ; Hayden MR
Eur J Hum Genet; 2011 May; 19(5):561-6. PubMed ID: 21248742
[TBL] [Abstract][Full Text] [Related]
15. Novel allele-specific quantification methods reveal no effects of adult onset CAG repeats on HTT mRNA and protein levels.
Shin A; Shin B; Shin JW; Kim KH; Atwal RS; Hope JM; Gillis T; Leszyk JD; Shaffer SA; Lee R; Kwak S; MacDonald ME; Gusella JF; Seong IS; Lee JM
Hum Mol Genet; 2017 Apr; 26(7):1258-1267. PubMed ID: 28165127
[TBL] [Abstract][Full Text] [Related]
16. Biallelic mutations in huntington disease: A new case with just one affected parent, review of the literature and terminology.
Uhlmann WR; Peñaherrera MS; Robinson WP; Milunsky JM; Nicholson JM; Albin RL
Am J Med Genet A; 2015 May; 167A(5):1152-60. PubMed ID: 25736541
[TBL] [Abstract][Full Text] [Related]
17. [Gene silencing approaches for the treatment of Huntington's disease].
Merienne N; Déglon N
Med Sci (Paris); 2015 Feb; 31(2):159-67. PubMed ID: 25744262
[TBL] [Abstract][Full Text] [Related]
18. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.
van Bilsen PH; Jaspers L; Lombardi MS; Odekerken JC; Burright EN; Kaemmerer WF
Hum Gene Ther; 2008 Jul; 19(7):710-9. PubMed ID: 18549309
[TBL] [Abstract][Full Text] [Related]
19. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides.
Southwell AL; Skotte NH; Kordasiewicz HB; Østergaard ME; Watt AT; Carroll JB; Doty CN; Villanueva EB; Petoukhov E; Vaid K; Xie Y; Freier SM; Swayze EE; Seth PP; Bennett CF; Hayden MR
Mol Ther; 2014 Dec; 22(12):2093-2106. PubMed ID: 25101598
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a predisposing background for CAG expansion leading to HTT mutation in a Chinese population.
Ma M; Yang Y; Shang H; Su D; Zhang H; Ma Y; Liu Y; Tao D; Zhang S
J Neurol Sci; 2010 Nov; 298(1-2):57-60. PubMed ID: 20864123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
